Designing and Undertaking a Health Economics Study of Digital Health Interventions by McNamee, P et al.
1 
 
Designing and Undertaking a Health Economics Study of Digital Interventions 
 
Working Group: Paul McNamee (convenor), Elizabeth Murray, Mike Kelly, 
Laura Bojke, Jim Chilcott, Alastair Fischer, Robert West, Lucy Yardley 
Abstract 
1. Scope 
This paper aims to discuss some of the key issues in the economic evaluation of digital 
interventions, in order to stimulate debate so that the existing economic techniques may be 
refined or new methods developed.  The paper does not seek to provide definitive guidance 
on appropriate methods of economic analysis for digital health interventions. 
2. What are the unique issues raised by digital interventions within that scope? 
Digital health interventions may be best characterised as a complex intervention in a 
complex system.  Some digital health interventions may hold special characteristics that 
require non-standard methods of economic evaluation, either in terms of general study 
design, and wider measurement of costs and benefits.   
 
3. What are the key challenges? 
Key challenges relate to having an evaluation method, or system, that is sufficiently flexible 
that it can adapt to the changing nature of a digital health intervention, and can encompass 
interaction effects between the intervention and the wider environment.    
 
4. What are the potential solutions? 
To be further developed within the paper but at this stage it seems likely that economic 
evaluation of digital health interventions should consider the collection of system-level data 
as well as adopt a perspective to encourage wider measurement of costs and benefits than 
is conventionally the case with respect to evaluation of medicines, devices and procedures.   
 
5. What are the remaining dilemmas and research agenda? 





The aim of economic evaluation of digital health interventions is to inform decision-makers 
about the relative value for money of that intervention against its next best alternative.  With 
resource scarcity, it is argued that more efficient use of resources will flow if resources are 
allocated to those interventions where the magnitude of additional benefits relative to the 
magnitude of additional costs is greatest, subject to an identified budget constraint. 
 
To help in this task, several sets of guidelines for the design and conduct of economic analysis 
exist for economic evaluation studies in health care (e.g. ISPOR Task Force, Value in Health 
2015), but the extent to which these have been applied in a consistent fashion for digital 
health interventions has not yet been studied.  For instance, to the best of our knowledge, 
there are no existing reviews of published economic evaluations of digital health 
interventions, although the evidence base is clearly growing at a level that may permit such a 
review to be conducted in the near future.  In telemedicine and telecare, which may be 
component parts of some digital health interventions, systematic reviews of reviews highlight 
considerable diversity in findings, although the overall conclusions are that there is a lack of 
knowledge and understanding regarding costs and therefore cost-effectiveness (e.g. Ekeland 
2010; Mistry 2011), and that these mostly arise through lack of methodological rigour within 
the original published studies (Mistry 2014).     
 
The paper does not seek to provide definitive guidance on appropriate methods of economic 
analysis for digital interventions, but instead aims to highlight what we judge to be some of 
the key issues in the economic evaluation of digital interventions, in order to stimulate debate 
so that the necessary economic tools and methods may in due course be developed. The 
paper is organised along the following lines.  First, we describe existing guides and analytical 
frameworks that have been suggested for the economic evaluation of interventions applied 
to complex interventions.  Second, using selected examples of digital health interventions, we 
assess how well these interventions map to these in terms of study design.  Third, and finally, 
we propose key decision points in the design and conduct of economic evaluations in this 




Existing Analytical Frameworks 
 
1. ISPOR Good Research Practice Guide 
To enhance the conduct and reporting of trial-based economic evaluation studies applied to 
new medicines, medical devices and procedures, the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) has recently published an updated 
version of their good research practice guide (Ramsey et al 2015).  The guidance re-
emphasises the need to base economic evidence on effectiveness rather than efficacy, the 
benefits from direct data collection on resource use and health states (or other measures of 
effectiveness) from study participants rather than indirectly (such as mapping) and the 
importance of recognising that study design such as randomised controlled trials (RCTs) are 
complementary to model-based evaluations.  These recommendations appear salient for the 
evaluation of the digital health interventions.  For example, as also argued in a companion 
paper (Murray et al 2016), there is recognition that RCTs are not always appropriate as a 
means to establish effectiveness, and a similar argument holds for evaluation of cost-
effectiveness.   
 
In some specific areas however, the recommendations may be less appropriate for digital 
health interventions.  For example, where interventions are designed in order to bring about 
health behaviour change, it can be argued that they different from medicines, devices and 
procedures in terms of their intended mechanisms of action.  Here the notions of mechanism 
of the actions of effects being confined to biological interactions within single individuals have 
been significantly developed and refined, to accommodate importance of their interaction 
with the health and social care system, or indeed the wider social environment.     
 
One area in particular where there may be a need for a different approach relates to 
the use of intermediate (surrogate) measures of benefit.  The ISPOR Guide 
recommend that use of “intermediate (or surrogate)” measures should be avoided in 
the measurement of benefit wherever possible.  However, when the expected effects 
of an intervention are only likely to observed in the long-term, the Guide suggests that 
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surrogate measures may well be appropriate, as long as the relationship to “final” 
measures, e.g. mortality, health related quality of life, or well-being, is firmly 
established.   However, even a focus on surrogate measures may not be sufficient in 
circumstances where the intervention is expected to adapt and change over time, and 
where effectiveness and cost-effectiveness is theorised to closely related to the 
system or environment in which it is placed.  In short, existing guidelines such as the 
ISPOR Guide, which are available for medicines, devices and procedures, may fall short 
for some digital health interventions. 
2. MRC Framework for Complex Interventions 
 
Digital health interventions in some circumstances may be best characterised as a complex 
intervention in a complex system (Hawe et al 2004, Shiell et al 2008, Hawe et al 2009).   Within 
the MRC Framework for the Evaluation of Complex Interventions (Craig et al 2008), a complex 
intervention is one that “contains several interacting components, and other characteristics, 
such as the number and difficulty of behaviours required by those delivering or receiving the 
intervention”.   This creates of course a challenge in establishing which component or set of 
components are driving the effects that are observed.  Complexity may also refer to property 
of the system in which an intervention is implemented, as well as the intervention itself.  Shiell 
et al (2008) notes that “a complex system is one that is adaptive to changes in its local 
environment, is composed of other complex systems, and behaves in a non-linear fashion (i.e. 
change in outcome is not proportional to change in input)”.  Petticrew et al (2013) outline this 
further by drawing distinctions between intervention complexity, outcome complexity and 
causal pathway complexity as follows: 
 
 Intervention complexity: 
o Multiple, interacting components 
o Likely to be tailored, adapt or change over time 
 Outcome complexity: 
o Spillovers and externalities, i.e. outcomes go beyond the immediate recipient 




o Feedback loops, i.e. the uptake of the intervention may be affected by uptake 
by others, “social contagion” effect 
 Causal pathway complexity: 
o Multiple moderators and mediators of the relationship between intervention 
and outcomes, in particular strong influence of system characteristics (i.e. the 
setting/context of the intervention is important and likely to generate 
heterogeneity in costs and benefits, through differences in resource 
availability, culture, beliefs, attitudes, interpersonal relationships) 
o Non linear relationships between intervention resource inputs and multiple 
outputs, “phase” changes, i.e. sudden, unpredictable tipping points 
 
The key question is the extent to which digital health interventions map to the above types 
of complexity.  It is clear that some digital health interventions may align with the above 
classification more than others; for example, consider a health app for the management of 
type 2 diabetes - if additional input on the part of health care staff is required according to 
individual patient goals or preferences, or if the intervention partly comprises an element of 
feedback from health care staff or information exchange with other users, then it may useful 
for economic evaluation purposes to classify this as a complex intervention.  Conversely, other 
digital health interventions for the same condition may exhibit little or no complexity, if they 
require little or no interaction with health care professionals or other recipients. 
 
Taking forward these notions of complexity, Shiell et al (2008) draw out some lessons for 
economic evaluation; it is argued that, where a complex intervention lacks significant 
interaction with the setting, i.e. where the casual pathway is relatively simple, then perhaps 
they can be considered as black boxes and current methods of economic evaluation might be 
sufficient, i.e. identifying, measuring and valuing resource use and weighing that against the 
value of health or other outcomes that are produced.   However, where there is significant 
interaction with setting, there are potentially additional challenges for economic evaluation.  
These challenges include more difficult choices regarding what measures of effectiveness 
should be included, how the consequences should be valued, and how evaluation should be 
conducted.  These challenges may lead therefore to the need to conduct what might be 
termed a complex economic evaluation, e.g. attempting to estimate cost-effectiveness for 
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various sub-groups of patients according to the extent of their interaction with the system in 
question.  However as highlighted by Petticrew et al 2013, in the context of systematic 
reviews, it is still legitimate to conduct “simple” evaluations of complex interventions, by 
addressing “simple” questions, (e.g. what is the average change in health after intervention 
receipt, relative to usual care?).  In these situations, existing guidance such as the ISPOR Guide 
may well suffice.  Ultimately, the type of evaluation conducted will depend on the research 
question, the level of interaction between intervention and system/setting and the 
importance this has for generating heterogeneity in costs and benefits, and the needs of the 




Whether simple of complex, a key factor in the design of an economic evaluation of any 
intervention relates to judgement regarding the time frame for the expected effects to occur.  
This creates a challenge for digital health interventions, as the content of many interventions 
may evolve over time, and there may be a protracted period before benefits are observed.  
conventional, “simple” approaches to effectiveness and consequently to cost effectiveness 
within existing evaluations of digital health interventions have usually been built on the 
randomised controlled trial.  The RCT is designed to determine whether the relationship 
between a constant (the independent variable), and the outcome of the interaction it has 
with the environment or situation into which it is applied, is free from bias and that the 
interaction between the independent and the dependent variable is as un-confounded as 
possible.  So long as the intervention is constant, then this is appropriate and has been highly 
successful.  But many digital health interventions are by their very nature not constant, with  
many evolving while they are being implemented. As a result, the artificial nature of many 
trials may mean that they are not good vehicles to indicate the potential success of digital 
health interventions.   
 
If trials with randomisation at the individual level may not always be appropriate, what then 
are the alternative options?  Aside from cluster-randomisation, other study designs such as 
natural experiments offer a potential opportunity (Sanson-Fisher et al 2014).   For example, 
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the five test bed sites within NHS England may provide a vehicle to examine effectiveness and 
cost-effectiveness on a large scale (http://www.england.nhs.uk/wp-
content/uploads/2015/03/test-bed-prospectus.pdf.  However, the use of quasi-experimental or 
observational study designs to demonstrate effectiveness for economic evaluation purposes 
also carries with it  limitations, such as the problem of being unable to control for the 
influence of unobserved variables (REFS).  A more fundamental issue is that in many cases an 
evaluation will be needed by decision-makers before the digital intervention has been trialled, 
and in cases where a trial does proceed, by the time it is nearing completion, both its 
effectiveness and cost effectiveness will already be ‘known’ with sufficient accuracy before 
real-world data is available.  This may then provide disincentives for the future use of real-
world data to examine effectiveness and cost-effectiveness. This suggests that a decision-
theoretic approach will be required (or may be sufficient?) in some circumstances, such as 
where the intervention could not conceivably cause harm, and where the likely effect size 
would produce an estimate of cost-effectiveness that is well below currently acceptable 
thresholds (Threlfall et al 2015). For example, the PRIMIT handwashing intervention was 
designed for use in a flu pandemic; in this context, international dissemination of a fully 
automated digital intervention which reduces the spread of respiratory infection would be 
likely to result in healthcare savings and wider health and socio-economic benefits so great 
that the cost of the intervention becomes neglible. 
 
Within the framework of complex interventions in complex systems, a critical factor that may 
drive effectiveness  may be the extent of uptake by a social network or other relevant 
population. The argument here is that changes in the relevant health behaviour can be spread 
or transmitted from one individual to another within a particular social network; the parallel 
is earlier work on obesity and the idea that this is partly a social disease, through a clustering 
effect (Christakis & Fowler 2007).  In a similar fashion, the effectiveness and cost-effectiveness 
of digital health interventions may depend on diffusion through social networks for uptake 
and effect.  For example,  an internet-delivered handwashing intervention was shown to 
result in reductions in respiratory infection in the  user and also in family members who had 
not engaged with the intervention directly, and one can assume smaller effects spreading 
more widely, due not only to the reduction in infectious contacts from the user, but also due 
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to handwashing behaviour by the individual in their social network. In addition, there may be 
feedback loops and  potentially non-linear relationships, such as effectiveness at the 
individual level being partly dependent on nature of uptake at the group level (for example 
‘The GCC challenge’ www.gettheworldmoving.com).  
 
Since Christakis Christakis & Fowler 2007 there has been an explosion of epidemiological 
studies using social network analytical methods for describing and understanding these social 
network effects (for example, see Powell et al 2015). 
  However, there have been far fewer published attempts to use such methods as the basis 
for the design and evaluation of digital health interventions (Leroux et al 2013; Frerichs et al 
2013).  The MRC framework for evaluating complex interventions may provide an appropriate 
structure, placing models of theory, process and outcomes at the centre of a cycle of 
intervention design, evaluation and redesign.  However, the framework recognises the need 
to expand the range of experimental /comparative designs. With the development of 
experimental methods in social networks analysis still at a relatively early stage (El-Sayed et 
al 2012).   
 
), there is therefore ample scope for methodological development in health economic 
applications of social network analytic methods. A possible starting point may be a critical 
review of existing interventions and development of novel case studies in this area.  For 
example, an ongoing EU collaboration, INTEGRATE-HTA (www.integrate-hta.eu) is examining 
aspects of complexity relevant to complex interventions in complex settings. Many of these 
aspects are potentially relevant when considering DHIs; including the impact of multiple 
interacting agencies involved in the intervention and the wider system, problems with 
defining the intervention due to characteristics like flexibility, tailoring, self-organization, 
adaptivity and evolution over time, and issues of historicity or path dependence, whereby the 
evolution of the system through series of irreversible and unpredictable events means that 










Implications of Applying The Complexity Framework for Economic Evaluation 
of Digital Health Interventions 
 
Digital interventions have been used to do a variety of different things including to promote 
and support healthy behaviour, to be a source of information, to improve self-management 
of illness, including treatment adherence, to assist in monitoring of symptoms and delivery of 
treatments, and for general health and clinical education and implementation of best practice 
care.  It is highly likely that as technologies evolve and commercial opportunities manifest 
themselves a great many other uses will be found for these digital interventions.  Each of 
these uses has different objectives, different outcomes, and different mechanisms of action 
behaviourally. This suggests that applying conventional, standard methods of economic 
evaluation, such as cost utility analysis, as if the intervention in question is to all intents and 
purposes similar to a pharmacological agent, may well not be optimal in situations of 
complexity.  This has implications for the cost side as well as for the benefit side of economic 
evaluation, and also major challenges for selection of the appropriate modelling framework, 
outlined below  These relate to issues regarding inclusion of development costs, measurement 
of health –related quality of life, and the appropriate modelling framework.  
 
1. Inclusion of development costs plus maintenance & running costs, or only the latter? 
 




 Literature reviews, summarising available evidence on:  
o the condition addressed by the DHI (causes, treatments); 
o Interventions likely to be effective if delivered digitally (e.g. tailored 
content, behaviour change techniques, emotional support); 
 De novo research identifying user “wants and needs” 
 Costs of content development (in an academic setting, this is usually RA time 
+ clinical input + health psychology + other disciplines as needed) 
 Costs of design features (navigation, images, videos, graphics) 
 Costs of software features (interactivity, algorithms, tailoring) 
 Costs of user experience testing 
These costs can be quite substantial, varying according to the complexity of the DHI, but may 
well range from £20,000 (for a simple one session intervention) (Little et al 2013) to £500,000 
(or more) for a longitudinal, highly interactive intervention with extensive content, tailored 
to many different variables (Yardley et al 2014). Much of these costs relate to iterative 
development and evaluation of the intervention to maximise acceptability and feasibility, 
(Yardley et al 2015).  
In contrast, maintenance costs can be very low.  The minimum maintenance cost is hosting. 
Costs of hosting vary according to complexity of DHI and levels of security and response times 
required, but can be as little as £200 pcm. 
There are three additional considerations: 
 Most DHIs require regular updating to remain “the same”, e.g. where the DHI 
promises to deliver up-to-date information.  Updating is required for: a) content; b) 
navigation and visuals; and c) software.  As mainstream software manufacturers 
update their products, DHI that are not updated will cease to function.  
 As outlined in the companion paper on engagement (Yardley et al 2016), there is good 
evidence that  that DHIs alone are often not as effective as DHI + human support or 
facilitation, where the human input focuses on getting the patient (user) to use the DI 
as intended.  Unlike all other costs associated with DHI, which are fixed, these 
facilitation costs are variable costs as they will increase with each additional user.  
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 Interventions are likely to evolve unpredictably over time.  Such change makes 
reproducibility more challenging, and also may make data collection for costs 
extremely difficult if the change is quick and no measurement of resources use 
consequences was planned or undertaken.  Change may also be planned as part of the 
intervention, as noted above, outside of the study period.  It is important that this 
knowledge is built into the cost estimates, otherwise there is a danger that the costs 
incurred in a research study may not be fully reflective of resource use outside of that 
setting. 
 
Commercial companies will roll up the costs of development and maintenance, and work out 
a cost to users which covers these (equivalent to the cost that drug manufacturers charge for 
a given drug).  But in the new and rapidly evolving market of digital health interventions it can 
be extremely difficult to determine a realistic charge that will cover the costs of development 
and maintenance, since the likely reach of the product and the future costs of updating it as 
technology changes are both highly unpredictable, and likely to be affected by future changes 
in how digital interventions are regulated, accredited and purchased. Where the digital 
intervention will be deployed in a large, known population (such as users of a national service 
or large insurance company) it is easier to calculate realistic costs and cost-effectiveness for 
providing a digital intervention at scale. An enduring issue is the question of when it is 
appropriate to include developments costs.  They are not directly included in NICE Appraisals 
of medicines, but they are indirectly reimbursed through the price charged by a 
manufacturer.  The key consideration here is likely to be whether the evaluation is conducted 
from a payer perspective, societal perspective or some other perspective.  In some 
circumstances, e.g. from the perspective of a national health regulator such as NICE, the 
decision may be whether to develop a digital health intervention de novo and make it 
available as a public good, i.e. once it is provided to at least one individual, it can be provided 
to an unlimited number of other people at no further cost, e.g. a health app to collect 
individual data could be regarded as a public good.  Fixed costs of development, storage, data 
retrieval, and encryption would be required, and the payer (the NHS) would agree a sufficient 
price with the manufacturer to cover these costs, together with a potential mark-up to 
protect intellectual property.  Other perspectives than those of a national regulator can be 
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adopted, and other factors, such as whether the intervention is an existing product, may have 
implications for the inclusion or exclusion of product development costs within the 
evaluation. 
Taking both fixed and variables costs together, the marginal costs per additional user will tend 
to zero as the population size increases – so one important implication is that it is critical to 
have a good understanding of the realistic population size likely to receive and use the 
intervention in real settings, rather than the number of participants enrolled in a particular 
research study.  This is not a trivial task, requiring additional effort and data analysis (Lanham 
et al 2013; Ling 2012; & refer to data paper here in this issue).  
 




2. Is measurement of health-related quality of life sufficient? 
The measurement of benefit should relate to the purpose of the individual technology – what 
is it trying to achieve over a particular time frame? – as that acts as the key guide to how 
benefits are measured.  The standard main categories of benefit within economic evaluation 
include the following: 
 health effects in their natural units, e.g. % level of cholesterol reduction; 
 non-monetary valuation of healthy time and/or other outcomes, e.g. Quality Adjusted 
Life Years (QALYs); 
 monetary valuation of healthy time and/or other outcomes, e.g. willingness to pay to 
gain  % increase in healthy life years; 
Less common approaches include measurement of changes in well-being effects, although 
there is a growing literature, especially in the field of social care, e.g. measures of capability, 
the extent to which an individual feels it is possible for them to live a meaningful life, or 
measures of life satisfaction, are now becoming more common (Al-Janabi et al 2012). 
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 It is clear that many different interventions are designed to achieve different objectives , 
some of which may relate to reductions in service use.  For example, a number of DHIs have 
been developed for chronic conditions, such as diabetes and patients receiving warfarin, and 
are intended to reduce the need for monitoring visits with NHS staff. Outcomes have been 
measured as change in utilisation of health care resources, patient satisfaction with the 
service and maintained control of symptoms. For such DHIs it seems plausible to maintain an 
NHS perspective for costs and outcomes, i.e. only health effects and NHS&PSS costs may be 
deemed relevant for evaluation. (However, even here, taking a more holistic perspective, 
telehealth interventions for the purpose of monitoring symptoms commonly have additional 
patient benefits such as an increased patient reassurance and empowerment – or disbenefits 
such as anxiety and intrusiveness). For other DHIs however, the range of benefits may be 
much wider and individual health effects may take a long time to occur. These include internet 
based programs and apps aimed to encourage a lifestyle change, such as weight loss, exercise 
or sleep behaviour. While some of the benefits may constitute a change in health, others may 
include greater social inclusion (see GCC example above) and productivity changes. 
 
Finally, an important issue relates to safety.  There may be the potential for both intentional 
and unintentional harms.  For example, digital apps helping individuals to commit suicide or 
those that provide advice that is opposite to existing guidelines are available, and so there is 
a clear role for national regulation here, as opposed to evaluation.  Where harms are 
unintentional, for example, if they could lead to additional anxiety, or despondency, then it is 
important that these are captured in the evaluation. 
  
3.Appropriate modelling framework 
Finally, there is the challenge of bringing costs and benefits together in the appropriate 
modelling framework.  In order to conduct evaluation that accounts for the degree of 
complexity that is relevant to the intervention and setting, it is vital that economic modellers 
develop or apply tools to encapsulate individual and population level interactions, issues of 
health differences in populations and the vagaries of human psychology It is imperative not 
to default to simplified and unhelpful assumptions or heuristics about the nature of human 
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behaviour  (even if policy makers do regularly default to such a position!).  These models and 
the techniques to develop them must be embraced in any kind of attempt at economic 
analysis of digital health interventions.   In this context, there appears a role for agent-based 
modelling (e.g. Chalabi & Lorenc 2013; Maglio & Mabry 2011).  Within this approach, 
individuals can be modelled to make decisions autonomously as well as interact with other individuals 
and with their environment using individually tailored “behavioural rules”.  These  rules can be non-
linear (e.g. discontinuous) and time-dependent (e.g. agents adapt and learn from previous 
experience).   
 
Key Decision Points in the Design & Conduct of Economic Evaluations for DHIs 
 
There is considerable scope for variation in how a particular intervention is delivered to a 
potential user, and the way in which that user then interacts with that intervention and the 
wider environment.  Moreover, feedback mechanisms may be critical to the success of that 
intervention, such that the wider environment has a strong effect on how a recipient uses a 
particular intervention. In short, some digital health interventions may be best characterised 
as a complex intervention within a complex system, and within the class of complex 
interventions, they may hold special characteristics that require the following questions to be 
prioritised when one designs and conducts an economic evaluation: 
 
 Is the intervention complex? i.e. does it involve interaction with other care 
professionals and/or an individuals’ social network? What outcomes are expected 
from the intervention, if it proves to be effective? Is the causal pathway from 
intervention to outcomes a complex one? i.e. is there significant interaction between 
intervention and setting,  
 
 Is a complex economic evaluation appropriate? (e.g. can the research question be 
addressed using “standard” methods of economic evaluation which do not require 





 What role should economic analysis play in the design of digital interventions? (e.g. 
example, should measurement of individual preferences for the characteristics 
associated with different digital interventions be sought prior to development, or 
sought in evaluations of such interventions?) 
  
 
 What costs should be included in an economic analysis for the given study 
perspective? (e.g. should all the resources used in the development of the digital 
interventions be included? Alternatively, is it acceptable to focus solely on 
measurement of the health care resources and any other resources required in future 
maintenance and support of digital interventions?). 
 
 What benefits should be included in an economic analysis for a given study 
perspective? (benefits are likely to be multi-faceted and potentially span beyond 
health, creating a challenge for measurement, e.g. does engagement with digital 
interventions facilitate future employment prospects for some individuals? Are there 
other spin-offs?  Are there any negative effects?  What effect does the DHI have on 
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